Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jan 16;14(1):1374.
doi: 10.1038/s41598-024-52016-4.

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Guillaume Larid  1 , Guy Baudens  2 , Georges Tiemdjo-Djimaffo  3 , Pascal Coquerelle  4 , Vincent Goeb  5 , Marie Hélène Guyot  6 , Laurent Marguerie  7 , Frédéric Maury  8 , Eric Veillard  9 , Eric Houvenagel  10 , Jean-Hugues Salmon  11 , René-Marc Flipo  12 , Elisabeth Gervais  13
Affiliations
Observational Study

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Guillaume Larid et al. Sci Rep. .

Abstract

The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab pegol (CZP)) in axial spondyloarthritis (axSpA) depending on the line of treatment in real-life conditions. A multicentre retrospective observational study was conducted including 552 patients fulfilling the ASAS criteria for axSpA followed in the RIC-France register who began SC-TNFi between 01/01/13 and 08/31/2018 for a total of 824 prescriptions. Taking all lines of treatment into account, GOL had a significantly higher retention rate compared with ADA, ETN, and CZP with a mean retention length of 59 months. As first-line bDMARDs, GOL had a significantly higher retention rate compared with ADA and ETN. ETN had the best retention rate when prescribed as at least 3rd bDMARD. Taking all lines of treatment into account, female sex, peripheral disease, BASDAI at initiation, and line of treatment were predictive factors for treatment cessation. Primary inefficiency was the most frequent reason for treatment cessation. In conclusion, GOL showed the highest retention rate in axSpA. Male sex, absence of peripheral disease, and early line of prescription were associated with better SC-TNFi retention in axSpA.

PubMed Disclaimer

Conflict of interest statement

GL: NOVARTIS, GSK, AMGEN VG: MSD, UCB, Pfizer, Sanofi , novartis, Abbvie, Medac JHS: AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Viatris RMF: Abbvie, Pfizer, MSD, Celltrion EG: BMS, Sanofi-Aventis, Roche, Abbvie, Novartis, Pfizer, Galapagos, MSD, Janssen FM, GB, GTD, PQ, EH, EV, LM, MHG had no competing interest.

Figures

Figure 1
Figure 1
Retention rate of subcutaneous TNF inhibitors combining all lines of treatment. Comparison of retention curves with a log-rank test using Kaplan Meier curves; GOL: golimumab, CZP: certolizumab, ETN: etanercept, ADA: adalimumab.
Figure 2
Figure 2
Retention rate of subcutaneous TNF inhibitors prescribed as first-line bDMARDs. Comparison of retention curves with a log-rank test using Kaplan Meier curves; GOL: golimumab, CZP: certolizumab, ETN: etanercept, ADA: adalimumab.
Figure 3
Figure 3
Retention rate of subcutaneous TNF inhibitors prescribed as second-line bDMARDs. Comparison of retention curves with a log-rank test using Kaplan Meier curves; GOL: golimumab, CZP: certolizumab, ETN: etanercept, ADA: adalimumab.
Figure 4
Figure 4
Retention rate of subcutaneous TNF inhibitors prescribed as third-line bDMARDs. Comparison of retention curves with a log-rank test using Kaplan Meier curves; GOL: golimumab, CZP: certolizumab, ETN: etanercept, ADA: adalimumab.
Figure 5
Figure 5
Retention rate of subcutaneous TNF inhibitors at 12 (A) and 24 months (B) depending on the bDMARD line of treatment. GOL: golimumab, CZP: certolizumab, ETN: etanercept, ADA: adalimumab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann. Rheum. Dis. 2021;80:1511–1521. doi: 10.1136/annrheumdis-2021-221035. - DOI - PubMed
    1. van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017;76:978–991. doi: 10.1136/annrheumdis-2016-210770. - DOI - PubMed
    1. Sepriano A, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: A systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000396. doi: 10.1136/rmdopen-2016-000396. - DOI - PMC - PubMed
    1. Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A. Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer. Adherence. 2017;11:719–729. doi: 10.2147/PPA.S128665. - DOI - PMC - PubMed
    1. Kristensen LE, et al. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register. Arthritis Care Res. 2010;62:1362–1369. doi: 10.1002/acr.20258. - DOI - PubMed

Publication types